JUN and esophageal squamous cell carcinoma: Studies have also pointed out that VRK1 promotes cisplatin resistance by upregulating c-MYC through c-Jun activation and serves as a therapeutic target for esophageal squamous cell carcinoma (Liu et al., 2017).